These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 24332926)
21. Neuropilin-1 enforces extracellular matrix signalling via ABL1 to promote angiogenesis. Raimondi C Biochem Soc Trans; 2014 Oct; 42(5):1429-34. PubMed ID: 25233427 [TBL] [Abstract][Full Text] [Related]
22. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Ji JW; Mac Gabhann F; Popel AS Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3740-9. PubMed ID: 17890434 [TBL] [Abstract][Full Text] [Related]
23. The anti-angiogenic isoforms of VEGF in health and disease. Qiu Y; Hoareau-Aveilla C; Oltean S; Harper SJ; Bates DO Biochem Soc Trans; 2009 Dec; 37(Pt 6):1207-13. PubMed ID: 19909248 [TBL] [Abstract][Full Text] [Related]
24. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cébe Suarez S; Pieren M; Cariolato L; Arn S; Hoffmann U; Bogucki A; Manlius C; Wood J; Ballmer-Hofer K Cell Mol Life Sci; 2006 Sep; 63(17):2067-77. PubMed ID: 16909199 [TBL] [Abstract][Full Text] [Related]
25. The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Poltorak Z; Cohen T; Neufeld G Herz; 2000 Mar; 25(2):126-9. PubMed ID: 10829252 [TBL] [Abstract][Full Text] [Related]
26. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640 [TBL] [Abstract][Full Text] [Related]
27. Growing and shaping the vascular tree: multiple roles for VEGF. Ruhrberg C Bioessays; 2003 Nov; 25(11):1052-60. PubMed ID: 14579246 [TBL] [Abstract][Full Text] [Related]
28. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Fantin A; Herzog B; Mahmoud M; Yamaji M; Plein A; Denti L; Ruhrberg C; Zachary I Development; 2014 Feb; 141(3):556-62. PubMed ID: 24401374 [TBL] [Abstract][Full Text] [Related]
29. A compartment model of VEGF distribution in blood, healthy and diseased tissues. Stefanini MO; Wu FT; Mac Gabhann F; Popel AS BMC Syst Biol; 2008 Aug; 2():77. PubMed ID: 18713470 [TBL] [Abstract][Full Text] [Related]
30. Role of vascular endothelial growth factor in the response to vessel injury. Alvarez Arroyo MV; Caramelo C; Angeles Castilla M; González Pacheco FR; Martín O; Arias J Kidney Int Suppl; 1998 Dec; 68():S7-9. PubMed ID: 9839275 [TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Wang H; Keiser JA Circ Res; 1998 Oct; 83(8):832-40. PubMed ID: 9776730 [TBL] [Abstract][Full Text] [Related]
32. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity. Ottino P; Finley J; Rojo E; Ottlecz A; Lambrou GN; Bazan HE; Bazan NG Mol Vis; 2004 May; 10():341-50. PubMed ID: 15162095 [TBL] [Abstract][Full Text] [Related]
33. Differential actions of VEGF-A isoforms on perichondrial angiogenesis during endochondral bone formation. Takimoto A; Nishizaki Y; Hiraki Y; Shukunami C Dev Biol; 2009 Aug; 332(2):196-211. PubMed ID: 19464280 [TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514 [TBL] [Abstract][Full Text] [Related]
35. Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Wu FTH; Stefanini MO; Gabhann FM; Popel AS Methods Enzymol; 2009; 467():461-497. PubMed ID: 19897104 [TBL] [Abstract][Full Text] [Related]
36. A computational analysis of pro-angiogenic therapies for peripheral artery disease. Clegg LE; Mac Gabhann F Integr Biol (Camb); 2018 Jan; 10(1):18-33. PubMed ID: 29327758 [TBL] [Abstract][Full Text] [Related]
37. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Ebrahem Q; Chaurasia SS; Vasanji A; Qi JH; Klenotic PA; Cutler A; Asosingh K; Erzurum S; Anand-Apte B Am J Pathol; 2010 Jan; 176(1):496-503. PubMed ID: 19948826 [TBL] [Abstract][Full Text] [Related]